Key facts
- It has raised $128.6M; the latest was Accelerator/Incubator in Sep 2025.
- Notable investors include Innovate UK, Tech Nation Group, Canaan Partners, British Business Bank, Earlybird Venture Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Grey Wolf Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Grey Wolf Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Grey Wolf Therapeutics
Developer of a drug discovery platform intended to offer oncology therapies that focus on immune oncology. The company offers selective inhibitors, small-molecule therapeutics that change tumour antigen repertoires and regulate immune cell activity to overcome resistance to existing therapies, enabling cancer researchers, immunotherapy teams, and clinicians treating autoimmune disorders to access treatments that make diseased cells more visible to the immune system.
- Sector
- Healthcare
- HQ
- Abingdon, United Kingdom
- Founded
- 2017
- Employees
- 45
- Website
- greywolftherapeutics.com/
- Ownership
- Privately Held (backing)
Grey Wolf Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Grey Wolf Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Grey Wolf Therapeutics in its N-PORT filings yet. We sweep new filings monthly.